Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKD

Atsushi Tanaka, Takumi Imai, Muthiah Vaduganathan, Yosuke Okada, Satomi Sonoda, Keiichi Torimoto, Satoru Suwa, Hiroki Teragawa, Motoaki Miyazono, Makoto Fukuda, Keisuke Yonezu, Naohiko Takahashi, Yuichi Yoshida, Kenichi Tanaka, Michio Shimabukuro, Yuki Hotta, Masao Moroi, Hiroki Niikura, Keisuke Kid · 2026

Read Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKD by Atsushi Tanaka, Takumi Imai, Muthiah Vaduganathan, Yosuke Okada, Satomi Sonoda, Keiichi Torimoto, Satoru Suwa, Hiroki Teragawa, Motoaki Miyazono, Makoto Fukuda, Keisuke Yonezu, Naohiko Takahashi, Yuichi Yoshida, Kenichi Tanaka, Michio Shimabukuro, Yuki Hotta, Masao Moroi, Hiroki Niikura, Keisuke Kid (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13195771.txt.

Description

Atsushi Tanaka and co-authors, with the FIVE-STAR investigators, run a randomized trial of the drug finerenone in type 2 diabetes with kidney disease, in a 2026 paper. Finerenone already improved kidney and heart outcomes when added to standard blood-pressure drugs in this population. A pooled look at earlier trials, covering over twelve thousand patients, suggested that an early drop in urine albumin explains much of that benefit.

The trial therefore takes the urinary albumin-to-creatinine ratio as its focus, testing how finerenone moves this marker under randomized conditions. The authors frame the study as a check on the marker's role: if albumin falls early and tracks the gains, it can guide treatment decisions for these patients.

Catalog record

CREATORAtsushi Tanaka, Takumi Imai, Muthiah Vaduganathan, Yosuke Okada, Satomi Sonoda, Keiichi Torimoto, Satoru Suwa, Hiroki Teragawa, Motoaki Miyazono, Makoto Fukuda, Keisuke Yonezu, Naohiko Takahashi, Yuichi Yoshida, Kenichi Tanaka, Michio Shimabukuro, Yuki Hotta, Masao Moroi, Hiroki Niikura, Keisuke Kid
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE14 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13195771

Browse the full library · About the Tower of Babel